Other active comparator
Bimagrumab
OTHER_ACTIVE_bimagrumab
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD 2.94 (-8.58 to 13.76) | 0.21 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD 3.01 (-7.13 to 11.92) | 0.14 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.69 (0.73 to 7.85) | 0.13 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.28 (1.56 to 15.12) | 0.22 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.77 (0.90 to 7.87) | 0.28 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.78 (1.29 to 17.27) | 0.44 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 3.80 (1.33 to 10.00) | 0.33 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.02 (1.73 to 13.37) | 0.43 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.14 (0.36 to 3.54) | 0.50 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.54 (0.52 to 4.51) | 0.45 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.18 (1.60 to 11.20) | 0.28 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.39 (1.95 to 14.99) | 0.23 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.82 (0.33 to 1.82) | 0.90 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.86 (0.36 to 1.87) | 0.84 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.99 (0.22 to 3.37) | 0.86 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.55 (0.32 to 5.55) | 0.80 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.77 (1.97 to 7.41) | 0.21 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.92 (2.03 to 7.82) | 0.19 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.42 (0.09 to 1.45) | 0.88 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.53 (0.12 to 1.83) | 0.84 |